A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

3상 완료 NCT05931380

대상 질환	Obesity
임상 단계	3상
스폰서	Eli Lilly and Company
상태	완료
참여자 수	238 명
중재(약물)	Orforglipron
시작일	2023년 7월 31일
완료일	2025년 6월 19일
결과 공개일	2026년 7월 20일

요약

The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.

Percent Change From Baseline in Body Weight at Week 72

Baseline, Week 72 · percent change

Placebo QD	-0.63 ± 0.732 percent change
6 mg Orforglipron QD	-5.90 ± 0.866 percent change
12 mg Orforglipron QD	-8.69 ± 1.136 percent change
36 mg Orforglipron QD	-7.93 ± 1.063 percent change

p-value	<.001
LS Mean Difference (Final values)	-5.28 (95% CI -7.52–-3.03)

Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline

Baseline to Week 72 · Percentage of Participants

Placebo QD	15.00 Percentage of Participants
6 mg Orforglipron QD	45.90 Percentage of Participants
12 mg Orforglipron QD	61.40 Percentage of Participants
36 mg Orforglipron QD	58.33 Percentage of Participants

p-value	<.001
Risk Difference (RD)	30.36 (95% CI 15.09–45.62)

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

Ignite Pilot: Goal Setting in a Digital Weight Loss Intervention — Stanford University
Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects — University of Pennsylvania
Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
Time Restricted Eating for Weight Loss Maintenance — NYU Langone Health
Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Effect of PDE5 Inhibition on Adipose Metabolism in Humans — Vanderbilt University Medical Center

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.

English 한국어 日本語中文 Русский